Leitlinientherapie bei renaler Anämie

Vincent Brandenburg

doi:10.1055/s-0043-111900

Dialyse aktuell, Table of Contents

Dialyse aktuell 2017; 21(05): 242-246
DOI: 10.1055/s-0043-111900

Schwerpunkt | Nephrologie

Leitlinientherapie bei renaler Anämie

Was ist zu beachten?

Vincent Brandenburg

¹Klinik für Kardiologie, Universitätsklinikum der RWTH Aachen

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Eine Anämie trägt zu den Symptomen einer chronischen Niereninsuffizienz bei. Das Bestimmen von Blutbild und Parametern des Eisenhaushaltes gehört zum Routinemonitoring bei chronischer Niereninsuffizienz. Grundlagen der Anämietherapie sind das Ausschalten von behandelbaren Ursachen, „iron first“ und eine vorsichtige Anhebung des Hb-Wertes auf ca. subphysiologische Werte (10–12 g/dl). Eine ESA-Gabe zur Anhebung des Hb-Wertes auf bis zu 13 g/dl ist ausdrücklich nicht zu empfehlen. Die niedrigstmögliche ESA-Dosis zur Erzielung des Hb-Zielbereiches sollte gewählt werden. Somit müssen Ursachen für ein vermindertes ESA-Ansprechen ausgeschaltet werden. Die häufigste ist ein Eisendefizit.

Full Text

References

Literatur
1 Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619
2 Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1309-1319
3 Collins AJ, Li S, St Peter W. et al Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473
4 Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20: 345-349
5 World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization; 1968
5 KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease 2012. 2. Im Internet: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf Stand. 23.05.2017
7 Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011). 2012 2. 288-291
8 Besarab A, Bolton WK, Browne JK. et al The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
9 Besarab A, Goodkin DA, Nissenson AR. Normal Hematocrit Cardiac Trial Authors. The normal hematocrit study--follow-up. N Engl J Med 2008; 358: 433-434
10 Zehnder C, Zuber M, Sulzer M. et al Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992; 61: 21-25
11 Levin NW, Lazarus JM, Nissenson AR. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis 1993; 22: 3
12 Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999; 34: 1089-1095
13 Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 2009; 4: 755-762
14 Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300: 573-578
15 Beusterien KM, Nissenson AR, Port FK. et al The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
16 NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure. Am J Kidney Dis. 2006 47. (Suppl. 4)
17 Kaufman JS, Reda DJ, Fye CL. et al Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583
18 Locatelli F, Canaud B, Giacardy F. et al Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-369
19 Nissenson AR, Swan SK, Lindberg JS. et al Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-118
20 Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-1470
21 Weiner DE, Miskulin DC, Seefeld K. et al Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 2007; 18: 3184-3191
22 Wright DG, Wright EC, Narva AS. et al Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol 2015; 10: 1822-1830
23 Pisoni RL, Bragg-Gresham JL, Young EW. et al Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111
24 Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005; 20 (Suppl. 04) iv9-iv15
25 Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15: 398-406
26 Bennett CL, Luminari S, Nissenson AR. et al Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-1408
27 Boven K, Stryker S, Knight J. et al The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353
28 KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
29 Berns JS, Elzein H, Lynn RI. et al Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
30 Lacson Jr E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-124
31 Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343
32 Locatelli F, de Francisco A, Deray G. et al Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract 2014; 128: 323-332
33 FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. 24.06.2011 Im Internet: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm Stand. 23.05.2017
34 Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15: 3154-3165
35 Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006; 47: 24-36
36 Parfrey PS. Target hemoglobin level for EPO therapy in CKD. Am J Kidney Dis 2006; 47: 171-173
37 Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388
38 Pfeffer MA, Burdmann EA, Chen CY. et al A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
39 Palmer SC, Navaneethan SD, Craig JC. et al Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33
40 Clement FM, Klarenbach S, Tonelli M. et al The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1104-1112
41 Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012; 82: 235-241
42 Collister D, Komenda P, Hiebert B. et al The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 472-478
43 Singh AK, Szczech L, Tang KL. et al Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
44 Churchill DN, Muirhead N, Goldstein M. et al Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 1994; 4: 1809-1813
45 Parfrey PS, Foley RN, Wittreich BH. et al Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
46 Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-828
47 Drüeke TB, Locatelli F, Clyne N. et al Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
48 Berns JS, Rudnick MR, Cohen RM. et al Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 1999; 56: 253-260
49 Beccari M. Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention. Int J Artif Organs 1994; 17: 5-13
50 Edmunds ME, Walls J, Tucker B. et al Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4: 1065-1069